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Optical imaging with the unassisted eye, along with palpa-
tion, are the primary guides for surgical oncologists. Together with
the subjective judgments of the surgeon, these sensory cues will
continue to serve as the mainstay for tumor resection procedures.
However, there is clearly a need for adjunct technologies to enable
greater resection accuracy by providing greater tumor-detection
sensitivity, higher spatial resolution, or increased quantitation and
reproducibility. Advanced radiographic approaches such as CT and
MRI are now routinely used to guide procedures that demand high
precision, such as neurosurgical resections, either through preop-
erative imaging in conjunction with real-time navigation techniques,
or through intraoperative imaging (1). However, the applicability of
these techniques is limited due to the high cost and complexity of
such radiographic approaches, as well as their limited resolution and
sensitivity, especially for guiding operative decisions at the surgical
margins where tumor burden is low or spatially disseminated. Here,
the value of optical imaging is highest, for although the ability of
light to penetrate deeply within tissues is poor, the exquisite sensitivity
and spatial resolution that can be achieved at superficial depths (e.g.,
near the final resection margins) is of significant utility in the sur-
gical armamentarium.
The recent early-stage clinical feasibility study by van Keulen
et al. in this issue of The Journal of Nuclear Medicine (2) provides
concrete examples of how fluorescence-guided surgery (FGS) can
affect surgical decision making. The first and most obvious exam-
ple is that of visualizing residual tumor at the base (‘‘deep margin’’)
of a resection cavity after the surgeon has determined that resection
is complete based on conventional means (i.e., visual and tactile
feedback). Another example is identifying an unanticipated second-
ary lesion that is missed during standard visual inspection.
A confounding factor alluded to by van Keulen et al. (2) is the
organ-specific definition of an acceptable margin of benign tissue
that must exist between the excised tumor and the surgical margin
surface (i.e., the ‘‘inked margin’’). Here, one must recognize that
current criteria for margins have evolved, in part, to compensate
for the limitations of conventional postoperative histology, in
which small numbers of thin tissue sections are imaged in the
vertical (depthwise) direction, often at intervals of several millime-
ters (i.e., bread-loafing). The ability to comprehensively image the
entire surgical margin surface with FGS should therefore motivate
new bespoke criteria for surgical completeness. Such criteria will
invariably be optimized and tailored over time to reflect our evolv-
ing understanding of the underlying biology and spatial character-
istics of a specific disease, and as clinical studies reveal outcomes
benefits (3). Central to this analysis is also an understanding of the
targeting behavior of the specific fluorescent contrast agent being used.
Just as surgical-margin criteria cannot not be generalized across
disparate diseases, a diverse array of FGS technologies have been
developed to address specific clinical applications. As described in
van Keulen et al. (2), low-resolution fluorescence surgical micros-
copy is the most-popular FGS approach in which numerous im-
aging platforms are now available (4). These systems provide the
advantage of a wide-area view, often of the entire surgical field,
but are limited in terms of detection sensitivity and the subjective
nature of the imaging readout (5). Portable spectroscopy devices
and high-resolution imaging probes sacrifice field of view but
provide greater detection sensitivity and quantitative detection of
tumor-specific contrast agents at localized tissue regions (5). In the
case of high-resolution in vivo microscopes, microarchitectural
details that approach the gold-standard of histopathology may be
visualized in real time, both with and without the aid of exogenous
agents (5). Ultimately, a combination of low-resolution (wide-
area) and localized high-resolution detection techniques may be
of value for many resection procedures. For example, bulk tumor
and noncritical regions could be resected more aggressively under
wide-area FGS, whereas regions that are vital for cosmetic or
functional purposes could be resected with greater precision using
localized probing techniques. Finally, there is an important role for
‘‘closed-field’’ ex vivo imaging technologies for FGS, which, un-
like the aforementioned in vivo imaging approaches, allows for
greater control over optical parameters such as illumination inten-
sity and geometry, along with reduced interference from ambient
light background, all of which ultimately enables more-accurate and
quantitative visualization of tissue morphology and fluorescence
contrast. Downsides include lengthened procedure times and potential
degradation of image contrast and tissue quality after patient excision.
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A recent study by the same group led by Dr. Eben Rosenthal has
attempted to compare several in vivo and ex vivo FGS platforms (6).
As FGS approaches achieve varying levels of maturity, impro-
vements in image processing and analytics will likely play an
outsized role in their success and impact. Initial efforts have focused
on improving the robustness of signal acquisition in the presence of
confounding factors such as ambient light contamination as well as
misleading sources of image contrast such as changes in tissue-
optical properties, variations in signal due to tissue geometry (i.e.,
working distance and angle of incidence), and the nonspecific
accumulation of contrast agents due to passive mechanisms. Methods
for mitigating these issues have involved creative combinations of
hardware and image-processing methods, such as multispectral
detection (7) and ratiometric ‘‘paired-agent’’ methods, in which a
nonspecific control agent is simultaneously imaged with a targeted
agent to provide a means to normalize for the misleading sources
of contrast listed above (8). Future efforts in computational analysis
and machine learning are needed to assist with clinical interpretation
of FGS data. For example, van Keulen et al. (2) observe differences
in both the mean fluorescence intensity and the spatial heterogeneity
of FGS images obtained from benign and malignant tissue types.
Automated segmentation and classification algorithms, ideally trained
and validated through outcomes-based studies, can assist with
subtle pattern-recognition tasks but will face challenges similar
to others striving to implement artificial intelligence in health
care (9).
Clinical validation and adoption are the final measures of success
for FGS and other innovative approaches in medicine. Early successes
should pave the way for accelerated translation of subsequent
technologies. As a benchmark example, the phase 3 clinical study
on the use of 5-ALA for FGS of high-grade gliomas was published
by Stummer et al. in 2006 (10) and led to its regulatory approval in
the European Union in 2007. However, subsequent Food and Drug
Administration approval in the United States did not occur until a
decade later in 2017. Although regulatory approval represents a
real and complex challenge, adequate reimbursement of FGS tech-
niques is of equal, if not greater, concern for broad clinical adop-
tion by all but the most academically motivated institutions. Here,
translational researchers and commercial entities are challenged to
develop realistic financial models to demonstrate a compelling
value proposition to payers. Such models should extend beyond
the immediate financial benefits of reduced call-back surgeries for
patients with positive margins (e.g., breast cancer lumpectomy)
and include a long-term analysis of patient outcomes such as
progression to advanced metastatic disease, which results in exponen-
tial increases in the cost of care, as well as the financial implications
of the side effects caused by overtreatment (e.g., neurologic morbidity
in the case of brain tumor resections). The article by van Keulen
et al. (2) refers to the concept of clinically significant changes
brought on by FGS. Ultimately, reimbursement strategies will require
careful and precise definition of these clinically significant changes,
along with the attendant benefits and risks to the patient, as viewed
through the lens of the economics of care.
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